Vetera-DDW-25 A.U.V. deuterium-depleted anticancer drug was registered for the adjuvant therapy of neoplastic diseases of household pets (13\/99 FVM) in Hungary, in 1999. Its main indication is pre- and post treatment of surgical interventions or single treatment in the case of non-operable tumors. Vetera-DDW-25 is administered per os (orally). In 2010, the marketing authorisation of Vetera-DDW-25 was renewed, the Central Agricultural Office Directorate of Veterinary Medicinal Product qualified Vetera-DDW-25 as a paramedicinal product for the adjuvant therapy of neoplastic diseases of household pets (Reg. No. 084\/1\/2011 MgSzH \u00c1TI).<\/p>\n\n\n\n
Vetera-DDW-25 has been effective in combination with surgery when conditions allowed the excision of the tumor or as a single treatment. Mammary tumors in dogs and cats showed a response rate higher than 70%; more than 50% of the animals achieved complete recovery. Similar effectiveness was observed in dogs and cats bearing rectal tumors. More than 70% of cats with lymphoid leucosis achieved complete response.<\/p>\n\n\n\n
After recovery, it is advisable to make a 1 or 2 months repetition cure, once or twice a year depending on the type of cancer. Application of the product can fully eliminate the need of operation; alternatively, the tumor brought to regression by oral application of VETERA-DDW-25 can be safely removed surgically. The treatment has no harmful side effects, in many cases the animal's mood, motility and fur quality was substantially improved.<\/p>\n\n\n\n
VETERA-DDW-25 can also get a major role in tumor prevention. Long-term animal experiments and the practical application have both shown that cures of VETERA-DDW-25 (1.5-2 months yearly) can minimize the likelihood of cancer development. In case of breeds with inherited tendency to tumors (e.g. mammary cancer) preventive application in the offspring is advisable.<\/p>\n\n\n\n
Since the authorization of Vetera-DDW-25 no pharmacovigilance report (adverse drug reaction, extra-label use, human reaction associated with the use of the product, suspected lack of expected efficacy) has been received by the Directorate of Veterinary Medicinal Product.<\/p>\n\n\n\n